- Home
- KXIN vs CRIS Comparison
KXIN vs CRIS Comparison
Compare KXIN & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KXIN | CRIS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.0M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | KXIN | CRIS |
|---|---|---|
| Price | $1.71 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 124.9K | ★ 217.4K |
| Earning Date | 11-26-2019 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.11 | $0.33 |
| 52 Week High | $22.00 | $3,360.00 |
Technical Indicators
Market Signals| Indicator | KXIN | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 18.47 |
| Support Level | $1.23 | $0.34 |
| Resistance Level | $2.81 | $5.50 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.11 | 0.90 |
| Stochastic Oscillator | 87.88 | 9.67 |
Price Performance
Historical ComparisonAbout KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.